ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
But late-breaking data raise questions about lack of a dose response.
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.